Dyne Therapeutics Inc. shares DYN jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental ...

WALTHAM, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of ...

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, ...

Dyne Therapeutics Inc (NASDAQ:DYN) reported a loss for the second quarter on Monday. The company posted a quarterly loss of 97 cents per share, which met the analyst consensus estimate. “This quarter ...

Dyne Therapeutics, Inc. has announced a $275 million non-dilutive senior secured term loan facility with Hercules Capital, which includes an upfront funding of $100 million and the potential for an ...

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best small cap stocks with biggest upside potential. On August 4, Dyne Therapeutics announced that its investigational therapy, called DYNE-251, ...

Shares of Dyne Therapeutics (NASDAQ:DYN) dropped ~21% in the premarket on Tuesday after the company indicated a delay in filing for U.S. approval of DYNE-101, an experimental therapy for a rare muscle ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement from Dyne Therapeutics ( ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to ...